Home » Correction

Correction

Mar 11, 2005
Premium

RNAi News incorrectly reported last week that Cenix Bioscience has signed a deal with Schering expanding upon existing large-scale target screening projects. In fact,the arrangement is the companies’ first, and involves Cenix performing target validation for Schering, not target screening work.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Make Sense of It All

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

Variations on Results

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

This Week in Nature

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

Of Many Minds

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

Jun
19
Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

What's Popular?

In Gene Silencing/Gene Editing

  1. Stanford Researchers Develop Multiplexed, Precision Genome Editing Tool for Yeast

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.